TGFB2
TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
Overview
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes clinical 0.65, literature 0.99, genetic association 0.59, somatic mutation 0.19, animal model 0.51).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
- 1 · What it is
TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.
- 2 · What goes wrong in cancer
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
- 3 · How drugs use it
No product in this corpus aims at TGFB2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:11768 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P61812 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000092969 (association with cancer (MONDO_0004992) 0.57; per-cancer scores at or above 0.5: myelodysplastic syndrome 0.57 (GraphQL API, CC0))
Biology
Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively. Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2. Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus. Location: Secreted, extracellular space, extracellular matrix; Secreted (UniProt). Locus 1q41 (HGNC).
- Myelodysplastic syndromes / neoplasms: Open Targets association 0.57 with myelodysplastic syndrome (MONDO_0018881)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.92; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TGFB2" OR ABSTRACT:"TGFB2" OR TITLE:"transforming growth factor beta 2" OR ABSTRACT:"transforming growth factor beta 2" OR TITLE:"Transforming growth factor beta-2 proprotein" OR ABSTRACT:"Transforming growth factor beta-2 proprotein") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGFB2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetMYSM1
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetSAMD9
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetSAMD9L
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetTGFB1
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetTGFB3
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetMT-CO1
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetCDA
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.